A strain of human cytomegalovirus called Towne was isolated in WI-38 human fibroblast cell cultures from the urine of an infected infant. It was then passaged 125 times in WI-38, including three clonings, and a pool was prepared in the same cell substrate for use as a potential live attenuated vaccine. The Towne virus has a broad antigenicity and cross-reacts with the AD-169 strain. Several markers of the Towne virus were found which differentiated it from fresh isolates. One of these was resistance of the former to trypsin. The Towne virus was tested for freedom from oncogenicity or other harmful effects in preparation for tests in humans.
The incidence of intrauterine cytomegalovirus (CMV) infection in developed countries is about 1% (27) . Of the infected neonates, at least 10% suffer some brain damage (15) and a greater proportion sustain some degree of hearing loss (24) . In older populations, the syndrome of CMV infection after large-volume blood transfusion is a frequent and troublesome complication of cardiac surgery and exchange transfusion (3, 8, 11, 20, 21, 23) . Although the immunology of CMV infection is incompletely understood, and it is uncertain whether or not fetal infection is always the result of primary infection, it seemed prudent to begin efforts to develop a prophylactic that could be administered to prepubertal girls or to women prior to pregnancy, or to recipients of large-volume blood transfusions.
The possible objections to this decision to go ahead with research on human vaccination against CMV are presented in the Discussion.
Elek and Stern (9) MATERIALS AND METHODS CF antigen and precipitin antigen. Infected WI-38 monolayers were suspended in 0.25% trypsin, and the resulting cell suspensions were washed twice in phosphate-buffered saline to make 5% cell suspensions. These cell suspensions were disrupted by sonication for 2 min in a Raytheon sonic oscillator at 1 A and centrifuged at 2,000 rpm for 10 min. The resulting supernatant fluid was used as antigen in complement fixation (CF) or immunoprecipitin tests. The titer of the CF antigen was determined by checkerboard titration against a known positive serum. Control antigen from uninfected WI-38 cells was similarly prepared.
CF test. The test was carried out using the microtiter technique (25) . Two units of complement, 2 U of hemolysin, and a 2% suspension of sheep erythrocytes were used in the test.
Gel-precipitin test. Molten agarose (0.4%) dissolved in Ca-and Mg-free phosphate-buffered saline, pH 7.2, containng 0.01% merthiolate was added in 25-ml amounts to 9-cm glass petri dishes. Wells (8 mm In subsequent passages, except for the ones to be mentioned specifically, virus released from sonicated cells was added to the supernatant virus and the combined suspension was used as inoculum.
At passages 50, 60, and 70, the inoculum was diluted terminally, and the dilution containing one isolated focus of infection was used as the subsequent inoculum.
Preparation of virus pool. The Towne strain was sent to Recherches et Industries Therapeutiques laboratories at passage 117. Passage of cell-free virus was made there until passage 125, at which time the virus was frozen as seed virus. WI-38 cultures were inoculated with the seed virus, using maintenance medium without serum or antibiotics. Supernatant fluids harvested at 7 days were filtered through a 3-,um filter combined with a stabilizer and then lyophilized. Two batches of experimental vaccine were prepared at passage 128. They were freeze dried, and both were tested for safety and potency as described below.
The lyophilized virus was stable at 4 C or lower. After reconstitution the titer was 103°P FU/ml for batch 1 and 104-7 PFU/ml for batch 2. Neutralization of virus. Cell-free Towne virus could be completely neutralized by various antisera, including: human CMV-convalescent serum sold by Flow laboratories (CF titer 1/16) and diluted 1/10; hyperimmune guinea pig serum against AD-169; and hyperimmune rabbit serum against Towne, prepared by inoculation of 1 ml subcutaneously (106 PFU) at 1-week intervals for five inoculations. At various intervals indicated in the figure the tissue culture medium was removed, and the cells were trypsinized and resuspended in 2 ml of media. The cell suspensions were then subjected to sonication for Antigenic spectrum of Towne. The Towne strain appears to be related to AD-169 in the breadth of its reactivity. Two rabbit antisera to Towne each gave titers of 1/32 in a CF reaction against AD-169 or Towne. Both sera also produced precipitin lines against both antigens. These sera were produced by five weekly inoculations of partially purified virus (1 ml of a sucrose density gradient fraction containing 107 PFU plus 1 ml of complete Freund adjuvant). The sucrose gradient was prepared as described previously (10) . When negative and positive human sera were tested against 2 U of antigens prepared from Towne or AD-169, the results were virtually identical (Table 3) . Testing showed common precipitin and CF antigens between Towne and four other strains when tested against human antisera (Fig. 2) . CF antigens prepared from one low-passage fresh isolate (5386), AD-169, and Towne, when tested against an antiserum raised in rabbits against Towne virus, showed cross-reactivity. Two units A second marker is thermostability. Both Towne and AD-169 are stable for 24 h at 4 C, whereas C-87, Davis, and Kerr all have paradoxical instability at that temperature (29) .
Third, Kim and Carp (14) have recently reported that CMV strains Towne, AD-169, Davis, Espaillat, and UW are all resistant to 0.25% trypsin. We have confirmed that observation with Towne and have gone on to test other low-and high-passage strains. Low-passage viruses were decidedly more sensitive to 30 min of incubation in 0.25% trypsin at room temperature ( Table 4 ). The same phenomenon was observed at 37 C.
Test for oncogenicity. With respect to possible oncogenicity, four sorts of tests have been performed. The first was to inoculate live hightiter CMV into suckling mice treated with antilymphocyte serum. No tumors or mortality (except for deaths due to bacterial infection) were seen.
The second was to attempt to repeat Albrecht and Rapp's (1) work in hamster embryo cultures. High-titer live Towne virus (107 mean tissue cultures infectious doses/ml) and Towne virus inactivated with ultraviolet light for various periods of time up to 10 min were inoculated onto hamster embryo fibroblasts, which were INFECT. IMMUN. Objections to the development of attenuated vaccines to prevent fetal CMV infection fall under the headings of safety and efficacy. The questions of safety are three: (i) immediate reactions, (ii) possible oncogencity, and (iii) possible persistence of attenuated CMV in a latent stage. This paper cannot consider these issues in detail, but some comments are pertinent.
The Towne strain has been given intranasally and subcutaneously to adult volunteers. No infection resulted from intranasal administration to 18 volunteers. Subcutaneous inoculation of 10 volunteers produced antibody responses, but no central effects apart from local reaction and lymphycytosis in some subjects. General health remained good, and no virus excretion was detected (12a; S. A. Plotkin and J. D. Farquhar, unpublished data).
The 'main reasons for concern about the oncogenicity of CMV is the report of its transformation of hamster embryo cells by Albrecht and Rapp (1) and the apparent oncogenicity of some other herpes group viruses. The hamster cell transformation data are difficult to interpret in view of their having been acquired with ultraviolet-irradiated virus and in view of the transformation ability of other viruses which are apparently not oncogenic for humans (e.g., adenoviruses and simian virus 40). Although natural Marek's disease, Epstein-Barr virus, Herpesvirus saimiri, and herpes simplex type 2 are all possible or probable oncogenic viruses, it is reassuring to note that serial passage of Marek's disease virus resulted in a strain that was nononcogenic (4). Moreover, many live herpes group viruses indigenous to lower animals have been used extensively for veterinary vaccination, such as infectious bovine rhinotracheitis. The U.S. Department of Agriculture estimated that 72 million doses had been given in 1973 alone.
No evidence for oncogenicity of CMV in humans has been produced, although it is estimated that 6% of all units of transfused blood contain CMV (8, 11, 21 (7, 30 The seroepidemiological studies mentioned above (7, 30) show that at least a third of young women have had no prior exposure to CMV. A prospective study (18) and a single case report (6) testify to the risk to the fetus of primary infection of the mother during pregnancy. On the other hand, three instances of repeated infections in subsequent pregnancies of seropositive mothers have been reported: nevertheless, it is encouraging to note that in contrast to the first infection, which was symptomatic, the second infected siblings remained asymptomatic (26) .
Secondly, despite acknowledged strain differences, there is much evidence of cross-antigenicity (2, 12) . Actual observations of natural or artificial challenge with heterologous strains will be necessary to settle the importance of strain differences.
With regard to the question on efficacy of attenuated vaccines, at this point only surmise by analogy is possible. Osborn and Walker (19) showed that a partially attenuated strain of mouse CMV protected inoculated mice against later challenge. We propose in future experiments to test the hypotheses that protection against fetal infection by CMV can be elicited by prior vaccination and that the cellular immunity induced by a living virus will be necessary to provide that protection.
